CLL samples manifesting high-risk cytogenetic abnormalities similarly underwent apoptosis upon treatment with P1446A, albeit CLL samples with TP53 aberrations showed a slightly decreased susceptibility (Fig 1C). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.